摘要
盐酸托莫西汀为选择性去甲肾上腺素再摄取抑制剂，常用于治疗多动症等，虽未被美国食品药品管理局和中国食品药品管理局批准用于治疗发作性睡病，但国外文献报道用药后有较好的疗效。本文作者经患者及其家属知情同意后，使用盐酸托莫西汀治疗，患者嗜睡症状消失，随访中未见不良反应。我们刊登此文旨在鼓励医疗方面的探索和创新，提示该药对治疗发作性睡病的临床价值。
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2009年第12期862-863,共2页
Chinese Journal of Neurology
参考文献16
-
1Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet, 2001, 68:686-699.
-
2Chen L, Fong SY, Lam CW, et al. The familial risk and HLA susceptibility among narcolepsy patients in Hong Kong Chinese. Sleep, 2007, 30: 851-858.
-
3Mishima K, Fujiki N, Yoshida Y, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep, 2008, 31 : 1119-1126.
-
4Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol, 2002, 59 : 1553-1562.
-
5Ebrahim IO, Peacock KW, Williams AJ. Posttraumatic narcolepsy--two case reports and a mini review. J Clin Sleep Med, 2005, 1:153-156.
-
6Picchioni D, Hope CR, Harsh JR. A case-control study of the environmental risk factors for narcolepsy. Neuroepidemiology, 2007, 29 : 185-192.
-
7Selbach O, Haas HL. Hypocretins: the timing of sleep and waking. Chronobiol Int, 2006, 23: 63-70.
-
8Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med, 2007, 8 : 373-399.
-
9Doghramji PP, Lieberman JA, Gordon ML. Stay awake! Understanding, diagnosing, and successfully managing narcolepsy. J Fam Pract, 2007, 56(11 Suppl Stay) : S17-31.
-
10宿长军,张守信,刘煜,李柱一,林宏,杨婷.多导睡眠图在发作性睡病诊断中的应用[J].中华神经科杂志,2004,37(3):198-198. 被引量：2
同被引文献28
-
1Benca RM. Narcolepsy and excessive daytime sleepiness :Diagnostic considerations, epidemiology, and comorbidities [ J ]. J Clin Psychiatry, 2001,68 Suppl 13:5-8.
-
2Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy [J]. Lancet, 2007,369(9560) :499-511.
-
3Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes [ J ]. Neurotherapeutics, 2012,9 ( 4 ) : 739-752.
-
4American Academy of Sleep Medicine. International classification of sleep disorders : diagnostic and coding manual [ M ]. 2a ed. Westchester, IL: American Academy of Sleep Medicine, 2005 : 79-94.
-
5Nevsimalova S. The diagnosis and treatment of pediatric narcolepsy[J]. Curt Neurol Neurosci Rep, 2014,14(8) :469.
-
6Longstreth WT, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy [ J ]. Sleep,2007,30 ( 1 ) : 13-26.
-
7Sonka K, Susta M. Diagnosis and management of central hypersomnias [ J ] . Ther Adv Neurol Disord, 2012, 5 ( 5 ) : 297-305.
-
8Carter ME, Brill J, Bonnavion P, et al. Mechanism for hypocretin-mediated sleep-to-wake transitions[ J]. Proc Natl Acad Sci U S A, 2012, 109(39) :E2635-2644.
-
9Bourgin P,Zeitzer JM, Mignot E. CSF hypocretin-1 assessarentin sleep and neurological disorders [J]. Lancet Neuro1,2008,7 (7): 649-662.
-
10Nevsimalova S. Narcolepsy in childhood [ J ]. Sleep Med Rev, 2009,13(2) :169-180.
-
1抗抑郁剂：瑞波西汀—一种选择性去甲肾上腺素再摄取抑制剂[J].德国临床用药,1999,2(1):13-13.
-
2金玲,张卫东.瑞波西汀与帕罗西汀治疗首发抑郁症对照研究[J].临床心身疾病杂志,2013,19(3):281-282.
-
3陆小兵,杨东英,孙祺章,黄兴兵.瑞波西汀与丙米嗪治疗抑郁症的对照研究[J].中国行为医学科学,2006,15(9):815-815. 被引量：1
-
4徐光洪,齐培,王伟松.可乐定合并盐酸托莫西汀对Tourette综合征共病注意缺陷多动障碍的疗效观察[J].中国神经精神疾病杂志,2011,37(3):175-175. 被引量：1
-
5魏宏伟.治疗注意缺陷障碍的新药——托莫西汀[J].国外医学（儿科学分册）,2004,31(6):329-332. 被引量：10
-
6母发光,何海兰,欧阳颖.盐酸托莫西汀对注意缺陷多动障碍共病Tourette综合征的疗效观察[J].中华实用儿科临床杂志,2014,29(21):1665-1667. 被引量：3
-
7刘燕,高哲石.瑞波西汀——新型选择性去甲肾上腺素再摄取抑制剂[J].上海精神医学,2001,13(2):103-105. 被引量：14
-
8梁学清,李丹丹,黄忠威.茯苓药理作用研究进展[J].河南科技大学学报（医学版）,2012,30(2):154-156. 被引量：223
-
9唐高霞.稀土元素在医疗方面的开发应用[J].今日科技,1997,17(1):6-6.
-
10方武宏,侯霄,刘学龙,陈国良.盐酸维洛沙嗪及其有关物质的合成[J].中国药物化学杂志,2015,25(6):450-452. 被引量：1
